Emerging drugs for the treatment of scleroderma: A review of recent phase 2 and 3 trials.
Authors: Roofeh D, Lescoat A, Khanna D Abstract INTRODUCTION: Systemic sclerosis (SSc) has the highest case-specific mortality of all connective tissue diseases. Its underlying disease mechanism affects several organs and remains incompletely understood. Ongoing work clarifying its etiopathogenesis is helping to develop targeted therapy. AREAS COVERED: Several clinical trials have evaluated the safety and efficacy of agents targeting different mechanisms of this disease. This review article reviews those mechanisms and surveys four key recent phase II or III clinical trials that are contributing to the landscap...
Source: Expert Opinion on Emerging Drugs - October 20, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Authors: Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G Abstract INTRODUCTION: In recent years, ovarian cancer (OC) treatment has been enriched with many new target therapies, most of all antiangiogenic drugs and PARP inhibitors (PARPis), which have literally changed the natural history of the disease. The impressive results of immunotherapy in other malignancies, mainly melanoma and lung cancer, and the good signals of activity in gynecological neoplasms like cervical and microsatellite instable (MSI-H) endometrial cancer, opened the space to the intr...
Source: Expert Opinion on Emerging Drugs - October 15, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of Waldenstr öm macroglobulinemia.
Emerging drugs for the treatment of Waldenström macroglobulinemia. Expert Opin Emerg Drugs. 2020 Sep 21;:1-12 Authors: Despina F, Meletios Athanasios D, Efstathios K Abstract INTRODUCTION: Waldenström's Macroglobulinemia (WM) is an indolent lymphoma with uniquely distinct and heterogenous clinical and genomic profiles. Clonal lymphoplasmacytic cells secrete monoclonal IgM. More than 90% of patients harbor a mutation in MYD88 gene, leading to the constitutive activation of downstream pathways, involving BTK-mediated signaling. The use of BTK inhibitors has changed the treatment landscape of WM...
Source: Expert Opinion on Emerging Drugs - September 23, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of attention deficit hyperactivity disorder (ADHD).
Authors: Pozzi M, Bertella S, Gatti E, Peeters GGAM, Carnovale C, Zambrano S, Nobile M Abstract INTRODUCTION: Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting up to 5.29% of children and 2.5% of adults depending on the country considered. Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. These drugs are effective and safe for the majority of patients, whereas about 20% of treated patients do not tolerate current ...
Source: Expert Opinion on Emerging Drugs - September 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of Acromegaly.
Authors: Campana C, Corica G, Nista F, Cocchiara F, Graziani G, Khorrami K, Franco M, Boschetti M, Ferone D, Gatto F Abstract INTRODUCTION: Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered lifelong. To date, almost 30% of patients treated with the currently available medical therapies do not achieve biochemical control. AREAS COVERED: This review focuses on new drugs in development for acromegaly. In detail, we provide an overview of the new molecules designed to...
Source: Expert Opinion on Emerging Drugs - September 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.
Authors: Carnero Contentti E, Correale J PMID: 32910702 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - September 13, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

New drugs under development for COPD.
Authors: Lo Bello F, Hansbro PM, Donovan C, Coppolino I, Mumby S, Adcock IM, Caramori G Abstract INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by chronic bronchitis, emphysema, and remodelling. Its prevalence is increasing worldwide, however there are few effective therapies, and none of the treatments currently available prevent the progression of the disease or target all of the hallmark features. The development and progression of COPD is heterogeneous, which has hampered the development of new therapies. AREAS COVERED: In this review, we cover the emergence of th...
Source: Expert Opinion on Emerging Drugs - September 7, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging corticosteroid delivery platforms for treatment of diabetic macular edema.
Authors: Shah JN, Vaze A, Tang Lee Say T, Gillies MC, Fraser-Bell S Abstract INTRODUCTION: Diabetic macular edema (DME) is a leading cause of vision impairment. Low-grade inflammation is thought to play a critical role in its pathogenesis. Although vascular endothelial growth factor inhibitors are used first-line, not all eyes with DME respond optimally and may respond better to corticosteroids. Currently corticosteroids for DME are given intravitreally and require regular monitoring. There is an unmet need for longer lasting therapies and/or effective non-invasive therapies such as those given via oral or topical ...
Source: Expert Opinion on Emerging Drugs - August 23, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging therapeutics for the management of COVID 19.
Authors: Debnath S, Srivastava R, Omri A Abstract INTRODUCTION: The coronavirus-19 (COVID-19) disease pandemic can be characterized as the most critical and changeable hazard to healthcare systems in eras. The high fatality rate associated with coronavirus infection underlines the urgent need for an effective treatment to reduce disease severity and mortality. AREAS COVERED: A detailed search for treatments related to severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) was carried out using PubMed. Components of the virus relevant to the infectious mechanism were identified. We have highlighted all the ...
Source: Expert Opinion on Emerging Drugs - August 18, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Anti-Amyloid- β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs.
Anti-Amyloid-β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs. Expert Opin Emerg Drugs. 2020 Aug 10;: Authors: Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, Stallone R, Liguori A, Ciritella C, Daniele A, Bellomo A, Seripa D, Panza F Abstract INTRODUCTION: Currently available Alzheimer's disease (AD) therapeutics are only symptomatic, targeting cholinergic and glutamatergic neurotransmissions. Several putative disease-modifying drugs in late-stage clinical development target amyloid-β (Aβ) peptide and tau protein, the principal ...
Source: Expert Opinion on Emerging Drugs - August 13, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of neuromyelitis optica.
Authors: Duchow A, Chien C, Paul F, Bellmann-Strobl J Abstract INTRODUCTION: Evidence-based treatment options for neuromyelitis optica spectrum disorders (NMOSD) patients are beginning to enter the market. Where previously, there was only the exclusive use of empiric and off-label immunosuppressants in this rare and devastating central nervous system autoimmune disease. AREAS COVERED: In accordance to expanding pathogenetic insights, drugs in phase II and III clinical trials are presented in the context of the current treatment situation for acute attacks and immunopreventative strategies in NMOSD. Some such dr...
Source: Expert Opinion on Emerging Drugs - August 1, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of light chain amyloidosis.
Authors: Chakraborty R, Lentzsch S Abstract INTRODUCTION: Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insoluble amyloid fibrils derived from kinetically unstable light chains. Achieving a rapid and deep hematologic response is critical for long-term survival. AREAS COVERED: This review covers the existing and emerging treatment options for systemic AL, divided into anti-plasma cell and fibril-directed therapies. The anti-CD38 monoclonal antibody daratumumab has demonstrated an unprecedented hematologic response rate and will become the new standard-of-care...
Source: Expert Opinion on Emerging Drugs - August 1, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for treatment of focal segmental glomerulosclerosis.
Authors: Trachtman H Abstract BACKGROUND: Glomerulosclerosis represents the final stage of glomerular injury during the course of kidney disease and can represent a primary disturbance in disorders like focal segmental glomerulosclerosis or a secondary response to tubulointerstitial disease. Overall, primary focal glomerulosclerosis (FSGS), the focus of this review, accounts for 10-20% of patients of all ages who progress to end stage kidney disease. There are no FDA approved therapeutic options that effectively prevent or delay the onset of kidney failure. AREAS COVERED: Current immunosuppressive therapy and c...
Source: Expert Opinion on Emerging Drugs - July 31, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of diabetic retinopathy.
Authors: Striglia E, Caccioppo A, Castellino N, Reibaldi M, Porta M Abstract INTRODUCTION: Diabetic retinopathy (DR) is one of the main pathological features of the diabetes mellitus spectrum. It is estimated that in 2020 about 4 million people worldwide suffered from blindness or visual impairment caused by DR. Many patients cannot access treatment, mostly because of high costs, while others discontinue it prematurely due to the high number of intravitreal administrations required, or the occurrence of ocular complications, or discomfort in quality of life. AREAS COVERED: The aims of this paper are to summariz...
Source: Expert Opinion on Emerging Drugs - July 28, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of chronic pruritic diseases.
Authors: Fourzali K, Golpanian RS, Yosipovitch G Abstract INTRODUCTION: Chronic pruritus is non-histaminergic and mediated through a complex interplay of peripheral and central immune and neural pathways. Significant developments in the understanding of chronic pruritus have emerged and paved the way for new, emerging therapies. AREAS COVERED: This review details the emerging drug landscape for chronic pruritus treatment, focusing on monoclonal antibody agents that target key cytokines and their receptors as well as small molecule agents that inhibit mediators of the immune and neural pathways. The article prov...
Source: Expert Opinion on Emerging Drugs - July 28, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for small cell lung cancer: A focused review on immune checkpoint inhibitors.
Authors: Reddy HG, Qin A, Kalemkerian GP Abstract INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive malignancy that accounts for 15% of all lung cancers. It is characterized by initial responsiveness to therapy followed by rapid diseas progression that is relatively resistant to further treatment. Recently, the addition of an immune checkpoint inhibitor (ICI) to chemotherapy has improved survival in patients with advanced disease, the first advance in systemic therapy in SCLC in over 30 years. AREAS COVERED: In this review, we present an overview of SCLC with a focus on the scope of the problem and s...
Source: Expert Opinion on Emerging Drugs - July 21, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists.
Authors: Shah RA, Alkhouri N, Kowdley KV Abstract INTRODUCTION: The discovery of the farnesoid X receptor and its role in bile and lipid homeostasis has led to investigation of FXR agonists as a therapy in cholestatic disorders and in NAFLD. With increasing prevalence of obesity and metabolic syndrome, NAFLD has grown to become the most prevalent chronic liver disease, present in a quarter of the worldwide population. FXR agonists represent a promising avenue for this burgeoning disease with few options for pharmacologic therapy. AREAS COVERED: A brief overview of the epidemiology of NAFLD/NASH and a review of ...
Source: Expert Opinion on Emerging Drugs - July 21, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of Hidradenitis Suppurativa.
Authors: Folkes AS, Hawatmeh FZ, Wong A, Kerdel FA Abstract INTRODUCTION: Hidradenitis suppurativa (HS) is a severe, chronic inflammatory disorder that causes recurrent occlusion of hair follicles in the intertriginous regions of the skin. Mild to moderate HS has been successfully treated with oral antibiotics, topical therapy and lifestyle modifications. However, moderate to severe HS is known to be refractory to conventional treatments. Wide excision surgery is a treatment option for severe HS, but often leads to functional impairments. Additionally, recurrence is common. The proper management of moderate to seve...
Source: Expert Opinion on Emerging Drugs - July 17, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Authors: Fujino T, Suda K, Mitsudomi T Abstract INTRODUCTION: MET aberrations, including MET exon 14 skipping mutation and amplification, are present in ~5% of non-small cell lung cancer (NSCLC) cases, and these levels are comparable to the frequency of ALK fusion. MET amplification also occurs as an acquired resistance mechanism in EGFR-mutated NSCLC after EGFR tyrosine kinase inhibitors (TKI) treatment failure. Therefore, the development of therapies for activated MET is urgently needed. AREAS COVERED: This review summarizes (1) the mechanisms and frequencies of MET aberrations in NSCLC, (2) the efficacies an...
Source: Expert Opinion on Emerging Drugs - July 5, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Clinical trials and novel therapeutics in Dermatomyositis.
Authors: Chandra T, Aggarwal R Abstract INTRODUCTION: Currently, there are no proven drugs that are FDA approved for the treatment of dermatomyositis (DM), even though multiple clinical trials are ongoing to evaluate safety and efficacy of novel therapeutics in DM. The purpose of this review is to highlight the biological plausibility, existing clinical evidence as well as completed and ongoing clinical trials for various drugs in pipeline for development for use in dermatomyositis. AREAS COVERED: The drugs with the strongest evidence have been included in this review with a focus on the mechanism of their acti...
Source: Expert Opinion on Emerging Drugs - July 1, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Authors: Lee EK, Matulonis UA Abstract INTRODUCTION: Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated significant anticancer activity in cancers harboring homologous recombination deficiency (HRD), exemplified by high grade serous ovarian cancer (HGSC). PARP inhibitors (PARPi) are being used in women with newly diagnosed ovarian cancer as well as in the recurrent setting. PARPi combination therapies are in development. AREAS COVERED: This review discusses the treatment of ovarian cancer, key PARPi clinical trials, mechanisms of action of PARPi, and novel PARPi combination regimens under investig...
Source: Expert Opinion on Emerging Drugs - June 24, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials.
Authors: Barp A, Gerardi F, Lizio A, Sansone VA, Lunetta C Abstract INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease involving both upper and lower motor neurons and resulting in increasing disability and death 3-5 years after onset of symptoms. Over 40 large clinical trials for ALS have been negative, except for Riluzole that offers a modest survival benefit, and Edaravone that modestly reduces disease progression in patients with specific characteristics. Thus, the discovery of efficient disease modifying therapy is an urgent need. AREAS COVERED: Althou...
Source: Expert Opinion on Emerging Drugs - May 29, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Treatments in the COVID-19 pandemic: an update on clinical trials.
Authors: Tao YY, Tang LV, Hu Y PMID: 32447996 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - May 26, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging 5-HT receptor antagonists for the treatment of Schizophrenia.
Authors: Jones MT, Strassnig MT, Harvey PD Abstract INTRODUCTION: While antipsychotics have been generally successful in treating psychosis in schizophrenia, there is a major treatment gap for negative symptoms and cognitive deficits. Given that these aspects of the disease contribute to poor functional outcomes independently of positive symptoms, treatments would have profound implications for quality of life. The 5-HT2A- receptor has been considered a potential target for interventions aimed at negative and cognitive symptoms and multiple antagonists and inverse agonists of this receptor have been tested. ARE...
Source: Expert Opinion on Emerging Drugs - May 26, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Authors: AlShimemeri S, Fox SH, Visanji NP Abstract Introduction: Prolonged treatment with l-3,4-dihydroxyphenylalanine (L-DOPA) leads to the development of uncontrolled movements (L-DOPA-induced dyskinesias (LID)) in Parkinson's disease (PD). There is currently only a single approved drug for the treatment of LID, a long-acting preparation of the NMDA antagonist, amantadine, that has variable benefit and side-effects. Therefore, new treatments for LID remains an unmet in PD.Areas covered: We review the current strategies for the management of LID; the pathogenic mechanisms underlying the development of LID, which ...
Source: Expert Opinion on Emerging Drugs - May 6, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging muscarinic receptor antagonists for the treatment of asthma.
Authors: Matera MG, Belardo C, Rinaldi M, Rinaldi B, Cazzola M Abstract Introduction: The critical role of acetylcholine in asthma pathophysiology and the increase in vagal tone are the main reasons why a LAMA is a good choice in the treatment of the asthmatic patient. Tiotropium is the only LAMA approved for use in asthma in many countries but there is a real interest in developing novel LAMAs for the treatment of asthma, or at least to extend this indication to other LAMAs already on the market.Areas covered: Trials that have studied or are evaluating the role of LAMAs already on the market in asthma and possible...
Source: Expert Opinion on Emerging Drugs - April 22, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of primary biliary cholangitis.
Authors: Phaw NA, Dyson JK, Jones D Abstract Introduction: Primary biliary cholangitis (PBC) is a progressive inflammatory autoimmune cholestatic liver disease. Without treatment, it may result in fibrosis and eventually end stage liver disease. In addition to the disease burden, the symptom impact on the quality of life for PBC patients is significant. Ursodeoxycholic acid, and the second-line therapy Obeticholic acid, are the only available licenced treatments. Although there has been rapid development of novel therapies in recent years for the treatment of PBC, there are very few symptoms directed therapies.Area...
Source: Expert Opinion on Emerging Drugs - April 9, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging therapies in β-Thalassemia: towards a new era in management.
Emerging therapies in β-Thalassemia: towards a new era in management. Expert Opin Emerg Drugs. 2020 Apr 05;: Authors: Bou-Fakhredin R, Tabbikha R, Daadaa H, Taher AT Abstract Introduction: The thalassemias constitute one of the common inherited monogenic diseases worldwide, characterized by autosomal recessive inherited defects in the production of hemoglobin. Currently available conventional therapies have many challenges and limitations. Advances in understanding the underlying pathophysiology of β-thalassemia enabled clinicians and researchers to move towards the development of novel thera...
Source: Expert Opinion on Emerging Drugs - April 8, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging systemic drugs in the treatment of plaque psoriasis.
This article reviews systemic biologic and oral small molecule drugs currently undergoing clinical trials for the treatment of plaque psoriasis.Expert opinion: Many patients with psoriasis have mild disease, and many with mild disease do not seek medical care for their condition. Many patients with mild disease could be adequately treated with topical treatments and phototherapy; however, adherence and feasibility have often been an issue with these treatment types. There seems to be limited room for development of novel biologics, as the existing ones are extraordinarily safe, effective, and convenient with few injections...
Source: Expert Opinion on Emerging Drugs - March 22, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging therapies for the treatment of ulcerative colitis.
Authors: Pugliese N, Roda G, Peyrin-Biroulet L, Danese S Abstract Introduction: Ulcerative colitis (UC) is a chronic idiopathic autoimmune inflammatory disorder, primarily affecting the gastrointestinal system. There are many patients affected that do not respond well to therapy and many others to which there is a loss of efficacy every year. The proportion of patients who have already experienced anti-TNF therapy is constantly increasing, making the development of new drugs with alternative mechanisms of action an important need for the treatment of UC.Areas covered: This review aims on emerging drugs in the treat...
Source: Expert Opinion on Emerging Drugs - March 10, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Novel targeted therapies for the management of liver fibrosis.
Authors: Trivella JP, Martin P, Carrion AF Abstract Introduction: Prolonged liver injury results in tissue damage and replacement by extracellular matrix and fibrosis. Cirrhosis represents a leading cause of mortality worldwide and imposes a major financial burden on health care systems. Fortunately, fibrogenesis has proven to be reversible if halted early, encouraging the development of novel anti-fibrotic agents that may accelerate histological restoration. Preclinical data have elucidated numerous potential therapeutic targets and many anti-fibrotic agents are currently at various stages of clinical research.Are...
Source: Expert Opinion on Emerging Drugs - February 28, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist.
Authors: Parker WAE, Storey RF PMID: 32064955 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - February 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Actinic keratosis: where do we stand and where is the future going to take us?
Authors: Cramer P, Stockfleth E Abstract Introduction: Actinic keratosis (AK) is a chronic disease which is mainly located across areas of sun exposed skin. Clinical and subclinical lesions coexist across a large area resulting in a field cancerization. As these lesions have the potential to transform into invasive squamous cell carcinoma (iSCC), treatment is crucial. With global prevalence increasing, AK is expected to be the most common in situ carcinoma of the skin.Areas covered: In this article, we cover the established algorithm of treating AK and give an insight into the drugs under development. There are six...
Source: Expert Opinion on Emerging Drugs - February 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Managing autonomic dysfunction in Parkinson's disease: a review of emerging drugs.
Authors: Kulshreshtha D, Ganguly J, Jog M Abstract Introduction: Autonomic dysfunction is an integral part of Parkinson disease (PD) complex and can be seen both in early and advanced stages. There is a paucity of medicines available to manage autonomic dysfunction in PD and this adds to the considerable morbidity associated with the illness.Areas covered: The pathophysiology and the available therapeutic options of autonomic dysfunction seen in PD are discussed in detail. The potential targets for novel regimens are reviewed and the available literature on the drugs emerging in management of autonomic dysfunction ...
Source: Expert Opinion on Emerging Drugs - February 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Authors: Molica S, Gianfelici V, Levato L Abstract Introduction: In the last few years, the expansion of therapy with pathway inhibitors has revolutionised the treatment landscape of chronic lymphocytic leukemia (CLL). As matter of fact, ibrutinib, the first-in-class Bruton tyrosine kinase (BTK) inhibitor, became a milestone in the treatment of both naïve or relapsed/refractory CLL patients. Most patients treated with such an agent achieve durable clinical response, however, a deeper response is rarely reached and continuous treatment is required. Since ibrutinib-resistant CLL clones can develop in about 20% o...
Source: Expert Opinion on Emerging Drugs - February 1, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of vitiligo.
This study comprehensively summarises the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signalling pathways, which are the targets for newer drugs. JAK kinase signalling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant mechanisms and repigmenting mechanisms. Topical immunosuppressants may be an alternative to steroids in localised vitiligo. Newer repigmenting agents like basic fibroblast growth factors, afamelanotide have been included and a special emphasis is laid on the upcoming targeted immunotherapy.Expert opi...
Source: Expert Opinion on Emerging Drugs - January 22, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Correction.
Authors: PMID: 31914874 [PubMed - in process] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - January 10, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

What potential is there for LSD1 inhibitors to reach approval for AML?
Authors: Pandey MR, Wang ES PMID: 31914875 [PubMed - in process] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - January 10, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging serine-threonine kinase inhibitors for treating ovarian cancer.
Authors: Maoz A, Ciccone MA, Matsuzaki S, Coleman RL, Matsuo K Abstract Introduction: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation and progression of cancers. Experience in non-ovarian cancers suggests that STK inhibitors are active against tumors with specific molecular alterations.Areas covered: This review discusses STK inhibitors in active development in phase II/III clinical ...
Source: Expert Opinion on Emerging Drugs - November 24, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

New immunotherapy in the treatment of advanced renal cancer.
Authors: Muto A, Gridelli C Abstract Introduction: Metastatic renal cell carcinoma (mRCC) in recent years has been one of the diseases in the oncology that has experienced the greatest development of targeted therapies.Area covered: On one hand, more and more refined acquisitions of molecular biology are allowing a better sub-classification of this tumor, identifying new and peculiar biological profiles of patients with metastatic renal cancer that will soon be destined for increasingly tailored treatments. On the other hand, immunotherapy has, in a short time, redesigned the perimeter of our knowledge, entering cl...
Source: Expert Opinion on Emerging Drugs - November 23, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of onychomycosis.
Authors: Gupta AK, Stec N Abstract Introduction: Onychomycosis is a widespread nail disease, often occurring on the feet. It is a chronic and often recurring disease, which makes it difficult to eradicate. The infection may be caused by dermatophytes, non-dermatophyte molds, and yeasts. Traditionally, systemic antifungal medications have been used to treat this infection, but in recent years topical formulations have been the focus of research. Areas covered: This review outlines the current antifungal market and novel treatments currently in development or in experimental phases. It highlights a shift from systemi...
Source: Expert Opinion on Emerging Drugs - October 30, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging antibiotics for Community-Acquired Pneumonia.
Authors: Liapikou A, Cilloniz C, Palomepue A, Torres T Abstract Introduction: Community-acquired pneumonia is the most common infection leading to hospitalization and death in all age groups, especially in elderly populations. Increasing antibiotic resistance among the common bacterial pathogens associated with community-acquired pneumonia, especially Streptococcus pneumoniae and staphylococci, has made its empirical treatment increasingly problematic, highlighting the need for effective antibiotic therapy. Areas covered: We searched PubMed and ClinicalTrials.gov for English-language reports of phase III clinical t...
Source: Expert Opinion on Emerging Drugs - October 30, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for treating methicillin-resistant Staphylococcus aureus.
Authors: Bassetti M, Russo A, Carnelutti A, Wilcox M Abstract Introduction: In clinical practice, methicillin-resistant Staphylococcus aureus (MRSA) represents a major threat and has been associated with high rates of inadequate antibiotic treatment and significant increases in morbidity, mortality and overall healthcare costs. The association between the prescription of an inappropriate or delayed antibiotic and impaired clinical outcomes has been widely described. Areas covered: To address the threat of MRSA, many new therapeutic options with a peculiar activity against MRSA have been recently developed and appro...
Source: Expert Opinion on Emerging Drugs - October 10, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for the treatment of noninfectious uveitis.
This article discusses existing local and systemic applied treatments for ocular inflammation including corticosteroids, non-biologic, and biologic disease-modifying anti-rheumatic drugs (DMARD). Potential drugs being studied in clinical trials are introduced for both local and systemic use. Expert opinion: Treatment options for uveitis continue to expand. Still, more efforts and research are needed to better understand the mechanisms potentially leading to clinical trials. PMID: 31498689 [PubMed - as supplied by publisher] (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - September 11, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

An update on emerging drugs in osteosarcoma: towards tailored therapies?
Authors: Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M Abstract Introduction: Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operative chemotherapy with drugs that have been used since decades. Areas covered: This review is intended to summarize the new agents and therapeutic strategies that are under clinical evaluation in HGOS, with the aim to increase the cure probability of this highly malignant bone tumor, which has not...
Source: Expert Opinion on Emerging Drugs - August 15, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging protein kinase inhibitors for the treatment of multiple myeloma.
Authors: Lind J, Czernilofsky F, Vallet S, Podar K Abstract Introduction: Significant advances have been made during the last two decades in terms of new therapeutic options but also of innovative approaches to diagnosis and management of multiple myeloma (MM). Indeed, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies have fundamentally changed the landscape of MM treatment. However, while patient survival has been significantly prolonged, most patients relapse. Including the milestone approval of the first kinase inhibitor imatinib mesylate for chronic myeloid leukemia in 2001, 48 small mole...
Source: Expert Opinion on Emerging Drugs - July 23, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for primary Sj ögren's syndrome.
Emerging drugs for primary Sjögren's syndrome. Expert Opin Emerg Drugs. 2019 Jun;24(2):121-132 Authors: Gandolfo S, De Vita S Abstract Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune systemic disease characterized by a complex and not yet completely elucidated etiopathogenesis, where autoimmune manifestations coexist with different degree of lymphoproliferation, resulting in multiple possible scenarios extremely heterogeneous from patient to patient. Although considerable progress has been made in the identifications of potential novel therapeutic targets in recent years, the ...
Source: Expert Opinion on Emerging Drugs - July 10, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging angiogenesis inhibitors for non-small cell lung cancer.
Authors: Malapelle U, Rossi A Abstract INTRODUCTION: Angiogenesis represent a complex process crucial during embryo development, wound healing, and collateral formation for improved organ perfusion. Numerous stimulatory and inhibitory pathways through their balance regulate angiogenesis and vascular homeostasis. Targeting the pathways implicated in the regulation of angiogenesis and neo-angiogenesis play an important role in cancers research, treatment and patients' outcome. Antiangiogenic strategies, including monoclonal antibodies binding vascular endothelial growth factor (VEGF) or the corresponding receptor and...
Source: Expert Opinion on Emerging Drugs - May 17, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for essential thrombocythemia.
Authors: Masarova L, Verstovsek S Abstract INTRODUCTION: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. Treatment has mostly focused on decreasing the risk of complications, especially prevention of thrombotic or hemorrhagic events. Areas covered: Over recent years, the treatment options of ET have been expanding with some novel agents on the horizon. The classes of agents described in this review include targeted and immunomodulatory agents, such as JAK1/2 inhibitors, int...
Source: Expert Opinion on Emerging Drugs - May 7, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research

Emerging drugs for progressive supranuclear palsy.
Authors: Giagkou N, Stamelou M Abstract INTRODUCTION: Progressive supranuclear palsy (PSP) is a common cause of atypical parkinsonism and a rapidly progressive disease that greatly burdens both patients and caregivers. Drugs with disease-modifying potential, targeting mechanisms implicated in the disease's pathogenesis are currently tested in Phase 1 and 2 trials. If proven efficacious, these compounds might provide substantial benefits not only to patients with PSP, but to patients with other tauopathies as well. Areas covered: Drugs in Phase 1 and 2 trials in PSP, and Phase 2 trials in other tauopathies (Alzheime...
Source: Expert Opinion on Emerging Drugs - April 23, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research